US6407132B1
(en)
*
|
1997-07-25 |
2002-06-18 |
James Black Foundation Limited |
Substituted imidazole derivatives and their use as histamine H3 receptor ligands
|
GB9718913D0
(en)
*
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
DE19816624A1
(de)
*
|
1998-04-15 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6319918B1
(en)
|
1998-06-04 |
2001-11-20 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones with kinase inhibitory activity
|
DE19824922A1
(de)
*
|
1998-06-04 |
1999-12-09 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
AU767138B2
(en)
|
1998-12-17 |
2003-10-30 |
F. Hoffmann-La Roche Ag |
4,5-pyrazinoxindoles as protein kinase inhibitors
|
PT1157019E
(pt)
*
|
1998-12-17 |
2003-06-30 |
Hoffmann La Roche |
4-alcenil (e alcinil) oxindolos como inibidores dequinases dependentes de ciclina em particular cdk2
|
DE69906149T2
(de)
*
|
1998-12-17 |
2003-12-18 |
Hoffmann La Roche |
4,5-azolo-oxindole
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
KR20010101266A
(ko)
|
1998-12-17 |
2001-11-14 |
프리돌린 클라우스너, 롤란드 비. 보레르 |
Jnk 단백질 키나제의 억제제로서의 4-아릴옥신돌
|
WO2000042213A1
(fr)
|
1999-01-13 |
2000-07-20 |
The Research Foundation Of State University Of New York |
Nouveau procede d'identification d'inhibiteurs de proteines kinase
|
GB9904932D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
|
GB9904933D0
(en)
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Compounds
|
US6492398B1
(en)
*
|
1999-03-04 |
2002-12-10 |
Smithkline Beechman Corporation |
Thiazoloindolinone compounds
|
GB9904930D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Thiazoloindolinone compounds
|
US6624171B1
(en)
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
US6391907B1
(en)
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
US6380235B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
GB9911053D0
(en)
|
1999-05-12 |
1999-07-14 |
Pharmacia & Upjohn Spa |
4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
|
DE19924401A1
(de)
*
|
1999-05-27 |
2000-11-30 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
CA2381821A1
(fr)
*
|
1999-08-27 |
2001-03-08 |
Boehringer Ingelheim Pharma Kg |
Indolinones substitues, leurs fabrications et leurs utilisations comme medicaments
|
ES2279769T3
(es)
*
|
1999-09-24 |
2007-09-01 |
Smithkline Beecham Corporation |
Mimeticos de trombopoyetina.
|
UA75054C2
(uk)
*
|
1999-10-13 |
2006-03-15 |
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг |
Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
|
US6762180B1
(en)
|
1999-10-13 |
2004-07-13 |
Boehringer Ingelheim Pharma Kg |
Substituted indolines which inhibit receptor tyrosine kinases
|
DE19949209A1
(de)
*
|
1999-10-13 |
2001-04-19 |
Boehringer Ingelheim Pharma |
In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
YU54202A
(sh)
|
2000-01-18 |
2006-01-16 |
Agouron Pharmaceuticals Inc. |
Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
|
HN2001000008A
(es)
|
2000-01-21 |
2003-12-11 |
Inc Agouron Pharmaceuticals |
Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
|
AU2001236720A1
(en)
|
2000-02-05 |
2001-08-14 |
Bemis, Guy |
Compositions useful as inhibitors of erk
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
WO2001079198A1
(fr)
|
2000-04-18 |
2001-10-25 |
Agouron Pharmaceuticals, Inc. |
Pyrazoles permettant d'inhiber des proteines kinases
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
US6534531B2
(en)
*
|
2000-04-27 |
2003-03-18 |
Bristol-Myers Squibb Company |
Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
|
WO2001082967A1
(fr)
*
|
2000-04-28 |
2001-11-08 |
Yamanouchi Pharmaceutical Co., Ltd. |
Compositions medicinales destinees a supprimer la production de ?-amyloide
|
CY2010012I2
(el)
|
2000-05-25 |
2020-05-29 |
Novartis Ag |
Μιμητικα θρομβοποιητινης
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
MXPA03001189A
(es)
|
2000-08-09 |
2004-05-14 |
Agouron Pharma |
Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas.
|
ATE295354T1
(de)
|
2000-08-18 |
2005-05-15 |
Agouron Pharma |
Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
|
WO2002020513A1
(fr)
*
|
2000-09-01 |
2002-03-14 |
Glaxo Group Limited |
Derives d'oxindole
|
WO2002020479A1
(fr)
*
|
2000-09-01 |
2002-03-14 |
Glaxo Group Limited |
Derives d'oxindole substitues utilises comme inhibiteurs de la tyrosine kinase
|
AU2001271611A1
(en)
|
2000-09-01 |
2002-03-22 |
Glaxo Group Limited |
Oxindole derivatives
|
EP1201765A3
(fr)
*
|
2000-10-16 |
2003-08-27 |
Axxima Pharmaceuticals Aktiengesellschaft |
Kinases cellulaires impliqués dans l'infection par cytomégalovirus et leur inhibition
|
US6638965B2
(en)
|
2000-11-01 |
2003-10-28 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
|
DE10054019A1
(de)
*
|
2000-11-01 |
2002-05-23 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
SE0101230L
(sv)
*
|
2001-04-06 |
2002-10-07 |
Innoventus Project Ab |
Ny användning av en tyrosinkinasinhibitor
|
DE10117204A1
(de)
|
2001-04-06 |
2002-10-10 |
Boehringer Ingelheim Pharma |
In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
KR20040000507A
(ko)
*
|
2001-05-24 |
2004-01-03 |
야마노우치세이야쿠 가부시키가이샤 |
3-퀴놀린-2(1h)-일리덴인돌린-2-온 유도체
|
ATE343415T1
(de)
|
2001-06-29 |
2006-11-15 |
Ab Science |
Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
|
ATE330608T1
(de)
|
2001-06-29 |
2006-07-15 |
Ab Science |
Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
|
JP2005500041A
(ja)
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
強力で選択的かつ非毒性のc−kit阻害剤
|
CA2461182A1
(fr)
*
|
2001-09-20 |
2003-05-01 |
Ab Science |
Utilisation d'inhibiteurs de la tyrosine kinase pour stimuler la pousse des cheveux
|
CA2461181A1
(fr)
*
|
2001-09-20 |
2003-05-01 |
Ab Science |
Utilisation d'inhibiteurs de c-kit puissants selectifs et non toxiques pour traiter des infections bacteriennes
|
CA2461812C
(fr)
*
|
2001-09-27 |
2011-09-20 |
Allergan, Inc. |
L'utilisation de 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones en tant qu'inhibiteurs de kinases
|
WO2003027109A1
(fr)
*
|
2001-09-27 |
2003-04-03 |
Allergan, Inc. |
3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones, inhibiteurs de kinase
|
WO2003033491A1
(fr)
*
|
2001-10-16 |
2003-04-24 |
Nippon Kayaku Kabushiki Kaisha |
Composition medicinale de prevention ou de soulagement d'effets secondaires chez les patients souffrant de cancer et composition anticancereuse medicinale
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
US7129225B2
(en)
*
|
2001-10-22 |
2006-10-31 |
The Research Foundation Of State University Of New York |
Protection against and treatment of hearing loss
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
EP1464645A1
(fr)
*
|
2001-12-18 |
2004-10-06 |
Kyowa Hakko Kogyo Co., Ltd. |
Derive d'indole
|
US7482366B2
(en)
*
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
ES2421511T3
(es)
|
2001-12-21 |
2013-09-03 |
X Ceptor Therapeutics Inc |
Moduladores de LXR
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
FR2836914B1
(fr)
|
2002-03-11 |
2008-03-14 |
Aventis Pharma Sa |
Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
|
JP2005523928A
(ja)
*
|
2002-04-30 |
2005-08-11 |
アルコン,インコーポレイテッド |
眼内圧の低下および緑内障性網膜症/眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子(ctgf)の活性および/または発現を調節するか、阻害するか、または調整する薬剤
|
AR040083A1
(es)
|
2002-05-22 |
2005-03-16 |
Smithkline Beecham Corp |
Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
DE10233500A1
(de)
*
|
2002-07-24 |
2004-02-19 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
|
US20040082615A1
(en)
*
|
2002-08-07 |
2004-04-29 |
Michael Konkel |
3-Imino-2-indolones for the treatement of depression and/or anxiety
|
TW200410937A
(en)
*
|
2002-08-07 |
2004-07-01 |
Synaptic Pharma Corp |
3-imino-2-indolones for the treatment of depression and/or anxiety
|
GB0225873D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Cyclacel Ltd |
Combination
|
WO2004048366A1
(fr)
*
|
2002-11-22 |
2004-06-10 |
Yamanouchi Pharmaceutical Co., Ltd. |
Derives 2-oxoindoline
|
AU2003290304A1
(en)
|
2002-12-23 |
2004-07-14 |
Astex Technology Limited |
Synthesis and screening of ligands using x-ray crystallography
|
CN102358738A
(zh)
|
2003-07-30 |
2012-02-22 |
里格尔药品股份有限公司 |
2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
|
TW200526638A
(en)
|
2003-10-22 |
2005-08-16 |
Smithkline Beecham Corp |
2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
|
GB0328180D0
(en)
*
|
2003-12-04 |
2004-01-07 |
Cyclacel Ltd |
Combination
|
DE102004012069A1
(de)
*
|
2004-03-12 |
2005-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
|
WO2005118551A2
(fr)
*
|
2004-05-28 |
2005-12-15 |
Ligand Pharmaceuticals Inc. |
Composes modulant l'activite de la thrombopoietine et methodes associees
|
AU2005299720B2
(en)
*
|
2004-10-25 |
2010-02-04 |
Ligand Pharmaceuticals Incorporated |
Thrombopoietin activity modulating compounds and methods
|
GT200500321A
(es)
*
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
BRPI0516915A
(pt)
|
2004-12-01 |
2008-03-11 |
Devgen Nv |
derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
|
EP1938691A3
(fr)
|
2004-12-17 |
2009-07-22 |
Devgen NV |
Compositions nematicides
|
PE20060777A1
(es)
*
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
WO2006101937A1
(fr)
*
|
2005-03-18 |
2006-09-28 |
Janssen Pharmaceutica N.V. |
Acylhydrazones en tant que modulateurs de kinase
|
WO2006119660A1
(fr)
*
|
2005-05-11 |
2006-11-16 |
Givaudan Sa |
Procede d'encapsulation
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
ES2651349T3
(es)
|
2005-06-08 |
2018-01-25 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta JAK
|
AU2006268174A1
(en)
*
|
2005-07-13 |
2007-01-18 |
Allergan, Inc. |
Kinase inhibitors
|
US7749530B2
(en)
|
2005-07-13 |
2010-07-06 |
Allergan, Inc. |
Kinase inhibitors
|
CA2602389A1
(fr)
*
|
2005-07-13 |
2007-01-18 |
Allergan, Inc. |
Inhibiteurs de kinase
|
GB0523041D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Cyclacel Ltd |
Combination
|
JP2009528295A
(ja)
|
2006-02-24 |
2009-08-06 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jak経路の阻害のための組成物および方法
|
WO2007117699A2
(fr)
*
|
2006-04-07 |
2007-10-18 |
University Of South Florida |
Inhibition de la proteine tyrosine phosphatase shp2/ptpn11 par nsc-87877, nsc-117199 et leurs analogues
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
US8217177B2
(en)
*
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
US8036664B2
(en)
*
|
2006-09-22 |
2011-10-11 |
Kineto Wireless, Inc. |
Method and apparatus for determining rove-out
|
BRPI0717805A2
(pt)
*
|
2006-10-06 |
2013-10-29 |
Irm Llc |
Inibidores de proteína quinase e métodos de uso dos mesmos
|
GB0625283D0
(en)
*
|
2006-12-19 |
2007-01-24 |
Cyclacel Ltd |
Combination
|
NZ578944A
(en)
*
|
2007-02-13 |
2011-03-31 |
Ab Science |
PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS
|
US20100143440A1
(en)
*
|
2007-04-30 |
2010-06-10 |
The Uab Research Foundation |
Ul97 inhibitors for treatment of proliferative disorders
|
ECSP077628A
(es)
|
2007-05-03 |
2008-12-30 |
Smithkline Beechman Corp |
Nueva composición farmacéutica
|
US7863315B2
(en)
*
|
2008-01-15 |
2011-01-04 |
Shenzhen Chipscreen Biosciences, Ltd. |
2-indolinone derivatives as selective histone deacetylase inhibitors
|
WO2009103032A1
(fr)
|
2008-02-15 |
2009-08-20 |
Rigel Pharmaceuticals, Inc. |
Composés de pyrimidine-2-amine et leur utilisation en tant qu’inhibiteurs des kinases jak
|
WO2009111644A2
(fr)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions et procédés pour diagnostiquer et traiter le cancer du pancréas
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
AU2009244897B2
(en)
|
2008-04-16 |
2014-11-13 |
Alexion Pharmaceuticals, Inc. |
2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
|
EP2116236A1
(fr)
|
2008-04-21 |
2009-11-11 |
Université de Mons-Hainaut |
Dérivés de bisbenzamidine pour une utilisation en tant qu'antioxydants
|
AU2009238590A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
WO2009135000A2
(fr)
*
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition de la protéine tyrosine phosphatase shp2/ptpn11 par nsc-117199 et analogues
|
US20110124634A1
(en)
*
|
2008-05-13 |
2011-05-26 |
Poniard Pharmaceuticals, Inc. |
Bioactive compounds for treatment of cancer and neurodegenerative diseases
|
CA2725295C
(fr)
*
|
2008-06-09 |
2016-11-08 |
Cyclacel Limited |
Combinaison de sapacitabine (cndac) et inhibiteurs de methyltransferase d'adn comme la decitabine et la procaine
|
WO2010039997A2
(fr)
*
|
2008-10-01 |
2010-04-08 |
The University Of North Carolina At Chapel Hill |
Protection hématopoïétique contre les composés chimiothérapeutiques au moyen d'inhibiteurs sélectifs des kinases dépendant des cyclines 4/6
|
CN102231983A
(zh)
*
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
|
WO2010121212A2
(fr)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Inhibiteurs d'échafaudage d'indoline shp-2 et procédé de traitement du cancer
|
JP2012526850A
(ja)
|
2009-05-13 |
2012-11-01 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
サイクリン依存性キナーゼ阻害剤及びその用法
|
JP2012528184A
(ja)
|
2009-05-29 |
2012-11-12 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
トロンボポエチンアゴニスト化合物の投与の方法
|
US20110028503A1
(en)
*
|
2009-07-28 |
2011-02-03 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
BR112012007137A2
(pt)
|
2009-09-30 |
2015-09-15 |
Harvard College |
metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
|
US8652534B2
(en)
|
2009-10-14 |
2014-02-18 |
Berry Pharmaceuticals, LLC |
Compositions and methods for treatment of mammalian skin
|
WO2011051452A1
(fr)
*
|
2009-10-29 |
2011-05-05 |
Palau Pharma, S.A. |
Dérivés hétéroaryles contenant n en tant qu'inhibiteurs de kinase jak3
|
US20120328568A1
(en)
|
2010-02-12 |
2012-12-27 |
Emory University |
Compositions and uses of lectins
|
US8815873B2
(en)
|
2010-03-02 |
2014-08-26 |
Amakem Nv |
Heterocyclic amides as rock inhibitors
|
CA2803697A1
(fr)
|
2010-06-25 |
2011-12-29 |
Facultes Universitaires Notre Dame De La Paix |
Derives de la beta-carboline utiles dans le traitement de troubles proliferatifs
|
US8785648B1
(en)
|
2010-08-10 |
2014-07-22 |
The Regents Of The University Of California |
PKC-epsilon inhibitors
|
EP2605804B1
(fr)
|
2010-08-18 |
2017-03-15 |
Emory University |
Composés et compositions pour ossification et procédés associés à ceux-ci
|
WO2012022780A1
(fr)
|
2010-08-19 |
2012-02-23 |
Université Libre de Bruxelles |
Dérivés d'acide 18β-glycyrrhétinique ayant une activité antitumorale
|
KR101929593B1
(ko)
|
2010-10-25 |
2018-12-14 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
WO2012058211A2
(fr)
|
2010-10-29 |
2012-05-03 |
Emory University |
Dérivés quinazoline, compositions et utilisations correspondantes
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
GB201019043D0
(en)
|
2010-11-10 |
2010-12-22 |
Protea Biopharma N V |
Use of 2',5'-oligoadenylate derivative compounds
|
AU2011329763A1
(en)
|
2010-11-17 |
2013-05-09 |
Brigham And Women's Hospital |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
|
WO2012075362A2
(fr)
|
2010-12-03 |
2012-06-07 |
Emory University |
Modulateurs du récepteur cxcr4 de la chimiokine et leurs utilisations
|
US8691777B2
(en)
|
2011-01-27 |
2014-04-08 |
Emory University |
Combination therapy
|
US9295754B2
(en)
|
2011-02-24 |
2016-03-29 |
Emory University |
Noggin inhibitory compositions for ossification and methods related thereto
|
US11179500B2
(en)
|
2011-02-24 |
2021-11-23 |
Emory University |
JAB1 inhibitory compositions for ossification and methods related thereto
|
EP2691095B1
(fr)
|
2011-03-31 |
2017-07-05 |
Emory University |
Composés d'imidazolylamide et leurs utilisations
|
WO2012140436A1
(fr)
|
2011-04-14 |
2012-10-18 |
Cyclacel Limited |
Régime posologique pour la sapacitabine et la décitabine en association pour le traitement de la leucémie myéloïde aiguë
|
US20140045936A1
(en)
|
2011-04-21 |
2014-02-13 |
Wake Forest University Health Sciences |
Cyclopropyl derivatives and methods of use
|
GB201107223D0
(en)
|
2011-04-29 |
2011-06-15 |
Amakem Nv |
Novel rock inhibitors
|
CA2835217A1
(fr)
|
2011-05-09 |
2012-11-15 |
Universiteit Antwerpen |
Sondes a base d'activite pour l'activateur du plasminogene de type urokinase
|
GB201108225D0
(en)
|
2011-05-17 |
2011-06-29 |
Amakem Nv |
Novel KBC inhibitors
|
WO2012177618A1
(fr)
|
2011-06-20 |
2012-12-27 |
Emory University |
Antagonistes du récepteur ep2 des prostaglandines, dérivés, compositions et utilisations associés
|
GB201113689D0
(en)
|
2011-08-09 |
2011-09-21 |
Amakem Nv |
Novel PDE4 inhibitors
|
WO2013028543A1
(fr)
|
2011-08-19 |
2013-02-28 |
Emory University |
Agoniste de bax, compositions et procédés associés
|
GB201114854D0
(en)
|
2011-08-29 |
2011-10-12 |
Amakem Nv |
Novel rock inhibitors
|
CA2846752A1
(fr)
|
2011-08-31 |
2013-03-07 |
Amakem Nv |
Biphenylcarboxamides utilises en tant qu'inhibiteurs de kinase rock
|
CN103930427B
(zh)
|
2011-09-30 |
2016-03-09 |
昂科迪塞恩股份有限公司 |
大环flt3激酶抑制剂
|
AU2012314035B2
(en)
|
2011-09-30 |
2016-12-15 |
Oncodesign S.A. |
Macrocyclic LRRK2 kinase inhibitors
|
GB201119358D0
(en)
|
2011-11-10 |
2011-12-21 |
Lewi Paulus J |
Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
|
DE102011119127A1
(de)
*
|
2011-11-22 |
2013-05-23 |
Merck Patent Gmbh |
3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
|
JP6039683B2
(ja)
|
2011-11-23 |
2016-12-07 |
ポートラ ファーマシューティカルズ, インコーポレイテッド |
ピラジンキナーゼ阻害剤
|
ES2958619T3
(es)
|
2012-01-30 |
2024-02-12 |
Univ Gent |
Compuestos anti-invasivos
|
GB201204756D0
(en)
|
2012-03-19 |
2012-05-02 |
Lewi Paulus J |
Triazines with suitable spacers for treatment and/or prevention of HIV infections
|
AU2013239816B2
(en)
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
WO2013181135A1
(fr)
|
2012-05-31 |
2013-12-05 |
Emory University |
Dérivés de quinazoline, compositions et utilisations associées
|
US9593125B2
(en)
|
2012-07-27 |
2017-03-14 |
Emory University |
Heterocyclic flavone derivatives, compositions, and methods related thereto
|
WO2014058921A2
(fr)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Inhibiteurs substitués de pyrimidinyl kinase
|
US9877981B2
(en)
|
2012-10-09 |
2018-01-30 |
President And Fellows Of Harvard College |
NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
US9682948B2
(en)
|
2012-11-05 |
2017-06-20 |
Emory University |
7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
|
WO2014072419A1
(fr)
|
2012-11-08 |
2014-05-15 |
Universiteit Antwerpen |
Nouveaux composés anti-vih
|
KR102275616B1
(ko)
|
2013-01-29 |
2021-07-09 |
레드엑스 파마 피엘씨 |
연성 rock 저해제로서 피리딘 유도체
|
JP6435315B2
(ja)
|
2013-03-15 |
2018-12-05 |
ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. |
高活性抗新生物薬及び抗増殖剤
|
WO2014145205A2
(fr)
|
2013-03-15 |
2014-09-18 |
St. Jude Children's Research Hospital |
Procédés et compositions de modulateurs de la transcription de p27kip1
|
ME03557B
(fr)
|
2013-03-15 |
2020-07-20 |
G1 Therapeutics Inc |
Protection transitoire de cellules normales pendant une chimiothérapie
|
AU2014230125A1
(en)
|
2013-03-15 |
2015-10-29 |
Oncodesign S.A. |
Macrocyclic salt-inducible kinase inhibitors
|
KR101548803B1
(ko)
*
|
2013-09-09 |
2015-09-01 |
경북대학교병원 |
3(6(4(트리플루오로메톡시)페닐아미노)피리미딘4일)벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
|
EP3043803B1
(fr)
|
2013-09-11 |
2022-04-27 |
Emory University |
Compositions à base de nucléotide et de nucléoside et leur utilisations
|
US10188738B2
(en)
|
2013-10-16 |
2019-01-29 |
Université Libre de Bruxelles |
Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
|
CN103588758A
(zh)
*
|
2013-11-04 |
2014-02-19 |
南京大学 |
一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用
|
JP6530393B2
(ja)
|
2013-11-12 |
2019-06-12 |
ヴリジェ ユニヴェルシテ ブリュッセル |
Rna転写ベクター及びその使用
|
WO2015081282A1
(fr)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
|
KR101602203B1
(ko)
*
|
2014-03-11 |
2016-03-11 |
경북대학교병원 |
N(2하이드록시에틸)3(6(4(트리플루오로메톡시)페닐아미노)피리미딘-4-일)벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
|
WO2015150337A1
(fr)
|
2014-04-01 |
2015-10-08 |
Amakem Nv |
Inhibiteurs de la lim kinase
|
US20170165240A1
(en)
|
2014-04-01 |
2017-06-15 |
Université Libre de Bruxelles |
New strategies for treating melanoma
|
US9717735B2
(en)
|
2014-04-17 |
2017-08-01 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
EP3140275B1
(fr)
|
2014-05-05 |
2020-07-08 |
Emory University |
Combinaison d'un antagoniste bh4 et d'un inhibiteur mtor pour le traitement du cancer du poumon
|
EP3143005B1
(fr)
|
2014-05-16 |
2021-07-07 |
Emory University |
Modulateurs des récepteurs ccr5 et cxcr4 de la chimiokine et et leurs utilisations
|
EP3180003B1
(fr)
|
2014-07-01 |
2022-01-12 |
The Regents of the University of California |
Inhibiteurs de pkc-epsilon
|
WO2016005340A1
(fr)
|
2014-07-08 |
2016-01-14 |
Universiteit Gent |
Analogues du hamamélitanin et leurs utilisations
|
WO2016040848A1
(fr)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Traitement de tumeurs rb-négatives en utilisant des inhibiteurs de la topoisomérase en association avec des inhibiteurs des kinases cycline-dépendantes 4/6
|
EP3191098A4
(fr)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinaisons et régimes posologiques pour traiter des tumeurs rb-positives
|
EA032872B1
(ru)
|
2014-09-17 |
2019-07-31 |
Онкодизайн С.А. |
Макроциклические ингибиторы rip2-киназы
|
SG11201701936WA
(en)
|
2014-09-17 |
2017-04-27 |
Oncodesign Sa |
Macrocyclic lrrk2 kinase inhibitors
|
WO2016083490A1
(fr)
|
2014-11-27 |
2016-06-02 |
Remynd Nv |
Composés pour le traitement de maladies associées à la substance amyloïde
|
CA2969372C
(fr)
|
2014-12-15 |
2023-05-16 |
Emory University |
Phosphoramidates pour le traitement du virus de l'hepatite b
|
ES2892123T3
(es)
|
2014-12-26 |
2022-02-02 |
Univ Emory |
Derivados antivíricos de N4-hidroxicitidina
|
WO2016146651A1
(fr)
|
2015-03-16 |
2016-09-22 |
Oncodesign Sa |
Inhibiteurs macrocycliques de récepteur kinase de type activine
|
KR20180006389A
(ko)
|
2015-04-28 |
2018-01-17 |
뉴사우쓰 이노베이션스 피티와이 리미티드 |
화학요법 및 방사선요법 유도 인지 장애, 신경병증 및 비활동성을 치료하기 위한 nad+ 표적화
|
EP4272820A3
(fr)
|
2015-05-29 |
2024-01-03 |
Emory University |
2-amino-n'-benzylidène-acétohydrazides et dérivés pour la prise en charge de maladies médiées par la protéine cftr
|
WO2016205806A1
(fr)
*
|
2015-06-18 |
2016-12-22 |
St. Jude Children's Research Hospital |
Procédés et compositions de prévention et de traitement de la perte d'audition
|
EP3423113B1
(fr)
|
2016-02-29 |
2020-09-02 |
Oncodesign S.A. |
Inhibiteur d'egfr macrocyclique radiomarqué
|
WO2017157882A1
(fr)
|
2016-03-14 |
2017-09-21 |
Université Catholique de Louvain |
Inhibiteurs de la voie de biosynthèse de la sérine
|
WO2017161253A1
(fr)
*
|
2016-03-18 |
2017-09-21 |
Tufts Medical Center |
Compositions et méthodes de traitement et de prévention de troubles métaboliques
|
CA3022119A1
(fr)
|
2016-04-28 |
2017-11-02 |
Emory University |
Compositions therapeutiques a base de nucleotides et nucleosides contenant un alcyne et utilisations associees
|
JP2019516715A
(ja)
|
2016-05-19 |
2019-06-20 |
ユニバーシタット アントウェルペン |
Par関連疾患の予防および/または治療における使用のためのビス(アセトアミドフェニル)グアニジノフェニルエチルホスホネート
|
BE1023757B1
(nl)
|
2016-06-30 |
2017-07-12 |
Yun NV |
Bewaring van micro-organismen
|
WO2018065387A1
(fr)
|
2016-10-04 |
2018-04-12 |
Universiteit Gent |
Nouveaux analogues du hamamélitannin et leurs utilisations
|
EP3532488A4
(fr)
|
2016-10-14 |
2020-04-29 |
Emory University |
Nanoparticules ayant des molécules qui lient ou bloquent pd-l1 et leurs utilisations dans le traitement du cancer
|
WO2018081442A1
(fr)
|
2016-10-26 |
2018-05-03 |
Emory University |
Complexes de polyoxométallate et leurs utilisations dans la prise en charge du cancer
|
EP3544952A1
(fr)
|
2016-11-24 |
2019-10-02 |
Universiteit Antwerpen |
Benzotropolones halogénées en tant qu'inhibiteurs d'atg4b
|
US10898544B2
(en)
|
2016-12-13 |
2021-01-26 |
Emory University |
Polypeptides for managing viral infections
|
BR112019013814A2
(pt)
|
2017-01-06 |
2020-01-21 |
G1 Therapeutics Inc |
método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
|
US20190388426A1
(en)
|
2017-01-30 |
2019-12-26 |
Université de Liège |
Perk and ire-1a inhibitors against neurodevelopmental disorders
|
IL309069A
(en)
|
2017-02-21 |
2024-02-01 |
Univ Emory |
CXCR4 cytokine receptor modulators and related uses
|
WO2018160967A1
(fr)
*
|
2017-03-02 |
2018-09-07 |
Board Of Regents, The University Of Texas System |
Dérivés d'indolinone utilisés comme inhibiteurs de la kinase de type fermeture éclair à leucine embryonnaire maternelle
|
CN106977508A
(zh)
*
|
2017-05-05 |
2017-07-25 |
遵义医学院 |
具有靛红结构的吡唑衍生物用于防治肿瘤的药物及其制法
|
PL3621963T3
(pl)
|
2017-05-11 |
2024-05-20 |
Remynd N.V. |
Związki do leczenia epilepsji, zaburzeń neurodegeneracyjnych i innych zaburzeń oun
|
US11661581B2
(en)
*
|
2017-05-25 |
2023-05-30 |
University Of Massachusetts |
Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
|
KR102659211B1
(ko)
|
2017-06-29 |
2024-04-18 |
쥐원 쎄라퓨틱스, 인크. |
G1t38의 형체 형태 및 그의 제조 방법
|
GB2581936B
(en)
|
2017-12-07 |
2021-02-10 |
Univ Emory |
N4-hydroxycytidine and derivatives and anti-viral uses related thereto
|
US20210145838A1
(en)
|
2018-04-05 |
2021-05-20 |
Universiteit Hasselt |
Selective pde4d inhibitors against demyelinating diseases
|
CN112654367B
(zh)
|
2018-06-29 |
2023-08-04 |
再青春生物医药公司 |
用于年龄相关性和/或变性疾病的药物组合
|
EP3833343B1
(fr)
|
2018-08-07 |
2024-02-21 |
Emory University |
Dérivés hétérocycliques de flavone, compositions et procédés associés
|
CN112839657A
(zh)
|
2018-08-24 |
2021-05-25 |
G1治疗公司 |
1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
|
CA3110661A1
(fr)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition de proteines kinases pour traiter la maladie de friedreich
|
PE20211054A1
(es)
*
|
2018-10-05 |
2021-06-07 |
Ichnos Sciences S A |
Compuestos de indolinona para uso como inhibidores de map4k1
|
CN114206864B
(zh)
|
2019-05-14 |
2024-05-24 |
苏州四体康宸医药科技有限公司 |
喹唑啉-2.4-二酮衍生物作为parp抑制剂
|
BR112022016733A2
(pt)
|
2020-02-24 |
2022-10-11 |
Univ Leuven Kath |
Compostos antivirais de pirrolpiridina e imidazopiridina
|
GB202003240D0
(en)
|
2020-03-05 |
2020-04-22 |
Ecosynth Nv |
Antiviral treatment
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
US11857551B1
(en)
|
2020-07-10 |
2024-01-02 |
Ting Therapeutics Llc |
Methods for the prevention and treatment of hearing loss
|
WO2022157381A1
(fr)
|
2021-01-25 |
2022-07-28 |
Universiteit Hasselt |
Phlorétine destinée à être utilisée dans le traitement de maladies neurodégénératives et démyélinisantes
|
KR20220128285A
(ko)
*
|
2021-03-12 |
2022-09-20 |
주식회사 온코크로스 |
항암제 내성 암의 치료를 위한 조성물
|
TW202320795A
(zh)
|
2021-07-26 |
2023-06-01 |
美商凱爾科迪股份有限公司 |
使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法
|
WO2023006893A1
(fr)
|
2021-07-30 |
2023-02-02 |
Confo Therapeutics N.V. |
Composés pour le traitement de la douleur, en particulier de la douleur neuropathique, et/ou d'autres maladies ou troubles associés à at2r et/ou à la signalisation médiée par at2r
|
EP4387629A1
(fr)
|
2021-08-18 |
2024-06-26 |
Katholieke Universiteit Leuven KU Leuven Research & Development |
Analogues de ribonucléoside 7-déazapurine 6-substitués et 6,7-disubstitués
|
WO2023046900A1
(fr)
|
2021-09-23 |
2023-03-30 |
Katholieke Universiteit Leuven |
Analogues de ribonucléosides dirigés contre le sars-cov-2
|
WO2023105283A1
(fr)
|
2021-12-08 |
2023-06-15 |
Fundacio Privada Institut De Recerca De La Sida - Caixa |
Inhibiteurs nucléosidiques de la transcriptase inverse destinés à être utilisés dans le traitement du syndrome de down et de la maladie d'alzheimer
|
WO2023111683A1
(fr)
|
2021-12-16 |
2023-06-22 |
Ascletis Bioscience Co., Ltd. |
Dérivés de n4-hydroxycytidine et leur utilisation comme agent antiviral
|
US11541071B1
(en)
|
2021-12-16 |
2023-01-03 |
Ascletis BioScience Co., Ltd |
Nucleoside derivatives and methods of use thereof
|
WO2023139402A1
(fr)
|
2022-01-18 |
2023-07-27 |
Ascletis Bioscience Co., Ltd. |
Inhibiteurs de cystéine protéases et leurs procédés d'utilisation
|
US11760722B2
(en)
|
2022-01-18 |
2023-09-19 |
Ascletis Bioscience Co., Ltd. |
Inhibitors of cysteine proteases and methods of use thereof
|
WO2023180567A1
(fr)
|
2022-03-24 |
2023-09-28 |
Fundacion Privada Institut De Recerca De La Sida-Caixa |
Cyclodextrines destinées à être utilisées dans une thérapie contre une infection à coronavirus
|
WO2023241799A1
(fr)
|
2022-06-15 |
2023-12-21 |
Université Libre de Bruxelles |
Flavanols destinés à être utilisés dans le traitement d'infections rétrovirales
|
WO2024009120A1
(fr)
|
2022-07-08 |
2024-01-11 |
Ascletis Bioscience Co., Ltd. |
Dérivés de triazine et leurs procédés d'utilisation
|
CN116514783A
(zh)
|
2022-11-21 |
2023-08-01 |
歌礼生物科技(杭州)有限公司 |
三嗪衍生物
|